Ann: Additional Information on Ground-breaking Research, page-66

Okay... Well everyone is aware that there were frustrations with management's communication in the past and failed Varm Cosmo deal, but I'm not sure how you can be venting this has a current issue.

Communication has been excellent this year. We have commercialised multiple MM pharma products in multiple countries and signed more distribution agreements, we have have achieved significant growth in non pharma revenue, and have made some excellent progress in our R&D side. I'm as frustrated with the SP as other shareholders, but to scapegoat management is absurd considering what we have achieved this year.

This is a long term hold, and as a few shareholders of mentioned, next qtrly should hopefully see a key boost in the SP.